This opinion was published in Times of India on April 02, 2023.
About the Authors
Aditya is currently a Senior Resident Fellow in the Research Director's Office at the Vidhi Centre for Legal Policy. He graduated from the NLSIU Bangalore in 2021 with a BA LLB (Hons). His areas of interest include constitutional law, civil procedure, and dispute resolution. He has academic publications on constitutional law, legislative drafting, and arbitration law in journals such as Statute Law Review and Arbitration International. At Vidhi, he has been providing legislative drafting assistance to various Ministries, Departments, and Authorities of the Central Government and various State Governments.
Shreyashi is a Research Fellow at Vidhi, and works in the area of public health. Her interests include public health, gender & sexuality, mental health, labour, and migration. She completed her B.A., LL.B. (Hons.) from the West Bengal National University of Juridical Sciences, Kolkata in 2016. Prior to joining Vidhi, she was engaged as a consultant to the District Administration, Ranchi. She worked on public health, nutrition, and education in mining-affected and other under-served areas of the district. As part of this engagement, she drafted the Guidelines on COVID-19 Preparedness and Control in Ranchi - and coordinated planning and implementation of health and social support mechanisms (domestic violence, mental health, migrant workers’ rights) during the pandemic. Apart from this, she has close to three years' experience as a researcher on open science and knowledge sharing with the Centre for Innovation, Intellectual Property and Competition at National Law University, Delhi. She co-authored the Open Science India Report, which seeks to guide government/ institutional policies for implementation of open science practices and inclusive research & knowledge ecosystems, especially in the Indian context.
18 Pharma Companies Lose Licenses: Why It Won’t Change Much For Drug Regulation
From lack of communication to a lack of accountability, drug regulations in India continue to be a mess.
Cough Syrup Deaths: India Must Focus On Systemic Gaps Over Pharma Reputation
Drug regulators must stop viewing incidents in the Gambia and Uzbekistan in isolation.Privacy & Cookies Policy